VIDEO: AVD-104 shows encouraging results in phase 2/3 study
Click Here to Manage Email Alerts
In this video, Rishi P. Singh, MD, discusses results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy, presented at the ASRS annual meeting in Stockholm.
The phase 2a data were based on a single-dose safety study of 30 patients with bilateral geographic atrophy (GA) who received one intravitreal injection of AVD-104 (Aviceda Therapeutics). Patients were followed for 3 months to assess safety and tolerability, and the researchers found no dose-limiting toxicity.
“What AVD-104 does is it works on both the repolarization of macrophages but also inhibits complement proteins and together might have a differential approach to the current GA therapies we have that are FDA approved,” Singh said.
Collapse
Singh R. Results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy: Glyco-immunologic modulation of macrophage activity. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts